Hypertension:高血压的严重程度介导了高尿酸血症与卒中的关系

2019-12-04 xing.T MedSci原创

由此可见,研究人员得出结论:高尿酸血症可能是卒中的危险因素。明显的顽固性高血压和大量降压药可显著减弱这一关联,表明严重高血压可能是介导因素。

在急诊科(ED),经常会观察到高血压(BP),但大部分用于短期内评估患者的健康状况。旨在探究ED测量的BP是否与长期的动脉粥样硬化性心血管疾病(ASCVD)、心肌梗死卒中有关,并评估筛查预防ASCVD所需的数量。

先前的研究并未广泛支持高尿酸血症作为卒中和其他心血管疾病的危险因素。近日,心血管权威杂志Hypertension上发表了一篇研究文章,研究人员使用REGARDS研究(卒中的地理和种族差异原因)的大量数据评估了高尿酸血症与缺血性卒中(约900例)之间的关系。

研究人员采用病例队列设计(突发性卒中病例和随机选择的队列参与者)和加权的Cox比例风险模型来估计血清尿酸水平≥6.8mg/dL(即高尿酸血症)和6.0-6.8mg/dL以及<6.0mg/dL(参考)作为对照与发生卒中之间的相关性。根据种族、性别和年龄对分析进行分层,研究人员评估了血清尿酸和卒中之间关联对心血管疾病合并症的介导作用。调整人口统计学变量以及收缩压和舒张压后,高尿酸血症与卒中相关(风险比为1.40[95%CI为1.10-1.78])。通过附加的协变量调整,这种联系被大大削弱了(风险比为1.17 [95%CI为0.90-1.51])。特别是明显的顽固性高血压(3种抗高血压药物或使用≥4种抗高血压药物且收缩压≥140mmHg或舒张压≥90mmHg)和抗高血压药种类显著降低了高尿酸血症对缺血性卒中的影响。具体而言,明显的顽固性高血压和抗高血压药的数量分别介导了这一关联的45%和43%。高尿酸血症和卒中之间的年龄、种族或性别之间的关联没有改变。

由此可见,研究人员得出结论:高尿酸血症可能是卒中的危险因素。明显的顽固性高血压和大量降压药可显著减弱这一关联,表明严重高血压可能是介导因素。 

原始出处:

Ninad S. Chaudhary.et al.Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study.Hypertension.2019.https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.13580

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2020-03-20 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 健健

    卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1728219, encodeId=51271e282197c, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Mar 20 08:48:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2039125, encodeId=c8dd203912571, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Wed Feb 19 10:48:00 CST 2020, time=2020-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476794, encodeId=b5bd14e6794f0, content=<a href='/topic/show?id=f915102342ea' target=_blank style='color:#2F92EE;'>#高尿酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102342, encryptionId=f915102342ea, topicName=高尿酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05f17331078, createdName=ms622625817193301, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501418, encodeId=7c3a150141821, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Thu Dec 05 22:48:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1026504, encodeId=2cc7102650444, content=卒中虽然是临床上常见病,溶栓,取栓等血管内治疗也很成熟,但是仍然有很多未知问题有待认知!, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=健健, createdTime=Wed Dec 04 10:48:00 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376478, encodeId=90f63e64784a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:41 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376477, encodeId=08703e647721, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:39 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376476, encodeId=32653e6476ab, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:36 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376475, encodeId=123c3e6475f7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:33 CST 2019, time=2019-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376474, encodeId=66e73e647405, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Wed Dec 04 08:29:31 CST 2019, time=2019-12-04, status=1, ipAttribution=)]
    2019-12-04 14794e5bm67(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

J Am Heart Assoc:国人家庭饮食习惯重男轻女!男士确诊高血压,家庭饮食习惯改善,女士患高血压则不然

对于高血压患者来说,饮食干预是非常重要的一种管理策略。大量证据表明,少吃盐、多吃含钾丰富的食物(水果、蔬菜、豆类)不仅有助于降压,还能降低心血管事件和死亡风险。

Neurology:生存偏倚可解释aSAH后吸烟者和高血压患者生存率改善

由此可见,aSAH后,吸烟和高血压与较差的生存率有关。早期和相反的结果可能是由于危险因素指标较少和医院危险因素研究固有的生存偏倚所致,这些研究缺乏关于尸检证实的院外死亡的信息。

JAMA Netw Open:健康的胖子?来看看超重中国人的高血压高血糖风险

肥胖与多种代谢并发症有关,包括2型糖尿病、高血压、中风、抑郁症以及某些类型的癌症。不过,生活中也总有“看似健康的胖子”,虽然体重超标,但倒是没有“三高”。这些人是真的受眷顾,代谢功能能够抗住体重的压力,还只是处于过渡期,问题尚未暴露?

Circulation:强化降低老年高血压患者的血压对大脑功能的影响

MRI显示以脑白质高信号为代表的皮层下微血管疾病与老年高血压患者的大脑功能减退有关。24小时平均收缩压(BP)水平患者的活动能力、白质疾病进展和认知功能有怎样的影响?研究人员开展一项前瞻性的、随机化研究,评估两个24小时平均收缩压水平对≥75岁的收缩期高血压患者的活动能力、白质疾病进展和认知功能的影响。MRI显示受试患者均有脑白质高信号病灶。将受试患者随机分至24小时平均收缩压≤130 mm Hg

Neurology: 50万国人随访10年!北大团队发现失眠与心血管疾病之间的联系!

众所周知,睡眠问题会影响身心健康。根据世界卫生组织统计,全球睡眠障碍率达27%。中国睡眠研究会2016年公布的睡眠调查结果显示,中国成年人失眠率高达38.2%,超过3亿中国人有睡眠障碍,而且这一数字仍在逐年攀升。

Hypertension:日常活动量与不同血压水平人群死亡率的相关性

如何确定对高血压患者心脏健康最大益处的运动量,一直都是一个挑战。Joseph等人开展一项研究探索日常体力活动水平与全因死亡率和心血管预后在不同血压水平上的相关性。在一项前瞻性心血管人群研究中,随机抽取了18 974名年龄在20到98岁之间的白人男性和女性。从体育活动问卷中收集自我报告的闲暇时间活动水平(I级:不活动;II级:少量活动;III级:中度-高强度活动)。血压分级:正常血压:<120